× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • The MINIMED Advanced Hybrid Closed-Loop (AHCL) system is an automated system for insulin delivery in persons with type 1 diabetes (T1D).
  • It is designed to maximize the glucose time in range (TIR) of 70-180 mg/dL.
  • The system auto basal adjusts every 5 minutes to target 100 or 120 mg/dL.

How was this study conducted?

  • The AHCL study investigated the use of the system.
  • The trial enrolled 157 individuals with T1D who were on pump therapy with or without continuous glucose monitoring.
  • Descriptive glycemic endpoints were used.
  • After the run-in patients were allocated to a glucose set point of 100 or 120 mg/dL for 45 days, and then crossed over to either 100 or 120 mg/dL.